You just read:

Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis

News provided by

Pfizer Inc.

Oct 07, 2010, 08:00 ET